文献速递生殖医学妇科

肯尼亚备孕女性细菌性阴道病与受孕力的前瞻性队列研究

Association between bacterial vaginosis and fecundability in Kenyan women planning pregnancies: a prospective preconception cohort study.
PubMed 文献 · Hum Reprod · 2021-01-01

共1376个月经周期中18.5%妊娠。调整年龄、无套性行为频率和研究点后,妊娠检测前就诊时BV与受孕力降低17%相关(aFR 0.83, 95%CI 0.6-1.1),持续性BV与受孕力降低43%相关(aFR 0.57, 95%CI 0.4-0.8)。

要点

  • 持续性BV与受孕力降低43%相关(aFR 0.57, 95%CI 0.4-0.8)。
  • 单次就诊时BV与受孕力降低17%相关,但95%CI跨1(aFR 0.83, 95%CI 0.6-1.1)。
  • 研究提示BV女性可能存在受孕力低下风险,需多组学方法进一步验证。

核心结论

  • 患有细菌性阴道病(BV)的女性可能面临受孕力低下的风险。
  • 持续性BV与受孕力降低43%相关(aFR 0.57, 95%CI 0.4-0.8)。

研究设计与样本

  • 每月进行 preconception 访视,采集阴道液标本并检测妊娠,共贡献1376个月经周期。
  • 采用离散时间比例概率模型估计受孕力比(FR)及95%CI。

主要发现

  • 1376个月经周期中18.5%(n=255)妊娠。
  • 调整年龄、无套性行为频率和研究点后,妊娠检测前就诊时BV与受孕力降低17%相关(aFR 0.83, 95%CI 0.6-1.1)。
  • 持续性BV(连续两次访视均BV)与受孕力降低43%相关(aFR 0.57, 95%CI 0.4-0.8)。

关键数值与推荐

  • BV定义为Nugent评分≥7。
  • 持续性BV定义为连续两次访视均检测到BV。
  • 主要结局为受孕力比(FR),采用离散时间比例概率模型估计。

临床怎么用

  • 对备孕女性可考虑筛查BV,尤其持续性BV可能提示受孕力降低风险。
  • BV与受孕力降低的关联提示治疗BV或改善阴道微生态可能有助于备孕。
  • 需结合分子方法进一步明确特定阴道细菌与受孕力的关系。

局限性

  • 使用革兰染色和唾液酸酶升高即时检测识别阴道微生态失调,非特异性方法可能遗漏个体细菌和菌群的关系。
  • 无套性行为报告为前一个月而非每个周期 fertile window,结果可能受残余混杂影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is bacterial vaginosis (BV) associated with fecundability? SUMMARY ANSWER: Women with BV may be at increased risk for sub-fecundity. WHAT IS KNOWN ALREADY: While BV has been associated with poor IVF outcomes, the association between vaginal microbiota disruption and non-medically assisted conception has not been thoroughly explored. STUDY DESIGN, SIZE, DURATION: Kenyan women with fertility intent were enrolled in prospective cohort that included monthly preconception visits with vaginal fluid specimen collection and pregnancy testing. Four hundred fifty-eight women attempting pregnancy for ≤3 menstrual cycles at enrollment were eligible for this fecundability analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: At monthly preconception visits, participants reported the first day of last menstrual period and sexual behavior, underwent pregnancy testing and provided vaginal specimens. Discrete time proportional probabilities models were used to estimate fecundability ratios (FRs) and 95% CI in menstrual cycles with and without BV (Nugent score ≥ 7) at the visit prior to each pregnancy test. We also assessed the association between persistent BV (BV at two consecutive visits) and fecundability. MAIN RESULTS AND THE ROLE OF CHANCE: Participants contributed 1376 menstrual cycles; 18.5% (n = 255) resulted in pregnancy. After adjusting for age, frequency of condomless sex and study site, BV at the visit prior to pregnancy testing was associated with a 17% lower fecundability (adjusted FR (aFR) 0.83, 95% CI 0.6-1.1). Persistent BV was associated with a 43% reduction in fecundability compared to cycles characterized by optimal vaginal health (aFR 0.57, 95% CI 0.4-0.8). LIMITATIONS, REASONS FOR CAUTION: Detection of vaginal microbiota disruption using Gram stain and a point-of-care test for elevated sialidase identified a non-optimal vaginal environment, but these non-specific methods may miss important relationships that could be identified by characterizing individual vaginal bacteria and bacterial communities using molecular methods. In addition, results may be subject to residual confounding by condomless sex as this was reported for the prior month rather than for the fertile window during each cycle. WIDER IMPLICATIONS OF THE FINDINGS: Given the high global prevalence of BV and infertility, an association between BV and reduced fecundability could have important implications for a large number of women who wish to conceive. Multi-omics approaches to studying the vaginal microbiota may provide key insights into this association and identify potential targets for intervention. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a National Institutes of Health grant (NICHD R01 HD087346-R.S.M.). R.S.M. received additional support for mentoring (NICHD K24 HD88229). E.M.L. was supported by pre- and post-doctoral fellowships (NIAID T32 AI07140, NICHD F32 HD100202). Data collection and management were made possible using REDCap electronic data capture tools hosted at the University of Washington's Institute of Translational Health Science supported by grants from NCATS/NIH (UL1 TR002319). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. R.S.M. receives research funding, paid to the University of Washington, from Hologic Corporation, and has received honoraria for consulting from Lupin Pharmaceuticals. L.E.M. receives research funding, paid to the University of Washington, from Hologic Corporation, and has received honoraria for service on scientific advisory boards from Hologic and Nabriva Therapeutics. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lokken EM, Manhart LE, Kinuthia J, et al. Association between bacterial vaginosis and fecundability in Kenyan women planning pregnancies: a prospective preconception cohort study. Hum Reprod. 2021. PMID: 33594429. doi:10.1093/humrep/deab002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。